LncRNAs are a class of RNA molecules with lengths ranging from 200 to 100,000 nucleotides. They regulate gene expression at various levels but do not encode proteins [
42,
43]. Several lncRNAs have unusually high expression levels in cancer cells and can function as oncogenes or tumor suppressors, participating in the formation and spread of tumor cells [
44]. They also contribute biologically to resistance to chemotherapy. Numerous studies have demonstrated a connection between chemotherapy resistance and changes in the expression levels of certain lncRNAs in OS tumor cells [
9,
45] (Table
2). LncRNAs play key roles in drug resistance. Generally, the levels of lncRNAs involved in OS drug resistance increase through a competitive endogenous RNA mechanism [
46‐
48].
Table 2
lncRNAs associated with osteosarcoma chemotherapy resistance
LncRNA TTN-AS1 | Via the miR-134-5p and MBTD1, controls drug resistance and apoptosis in OS cells | |
LncRNA KCNQ1OT1 | In OS, inhibiting resistance by controlling LARP1 mediated by miR-129-5p by knocking down KCNQ1OT1 | |
| OS cells become more sensitive to CDDP if KCNQ1OT1 is knocked out by increasing Kcnq1 expression through DNMT1 | |
LncRNA MIR17HG | OS resistance to cisplatin is aided by the SP1, MIR17HG, and miR-130a-3p | |
LncRNA FENDRR | Reduces the levels of ABCB1 and ABCC1 in OS cells, making them more sensitive to doxorubicin | |
LncRNA HOTAIR | Bolsters OS cells' cisplatin resistance via the STAT3 Axis of miR-106a-5p | |
LncRNA SNHG16 | Sponges miR-16 to increase ATG4B expression, which in turn increases cisplatin resistance | |
LncRNA NORAD | Regulates OS's sensitivity to drug resistance by targeting miR-410-3p | |
LncRNA ANRIL | Through targeted regulation of miR-125a-5p, OS cell sensitivity to cisplatin can be increased by inhibiting the expression of the lncRNA ANRIL | |
LncRNA-SARCC | Targets Hexokinase 2 to increase OS's sensitivity to cisplatin by inhibiting glycolysis through miR-143 | |
LncRNA MSC-AS1 | By binding to microRNA-142, downregulated lncRNA MSC-AS1 increases cisplatin sensitivity | |
LncRNA OIP5-AS1 | Sponging the miR-340-5p induces the LPAAT, PI3K, AKT, and mTOR signaling pathway, resulting in OS cisplatin resistance | |
| Through the miR-377-3p/FOSL2 axis, knockdown enhances cisplatin sensitivity in OS | |
LncRNA ROR | Sponges miR-153-3p to induce cisplatin resistance in OS | |
LncRNA NCK-AS1 | In OS cells, inhibiting the lncRNA NCK-AS1 modifies miR-137 to control cisplatin resistance | |
LncRNA DNAJC3-AS1 | Decreases OS's sensitivity to cisplatin, which was reversed by down-regulating DNAJC3, its sense-cognate gene | |
LncRNA HOTTIP | By activating the Wnt/-catenin pathway, lncRNA HOTTIP overexpression increases osteosarcoma cell chemoresistance | |
The researchers have confirmed that the lncRNA TTN-AS1 controls OS cell growth, apoptosis, and cisplatin resistance and promotes MBTD1 expression by targeting miR-134-5p [
49]. Patients with OS showed high levels of lncRNA expression. Drug resistance can also be reduced by downregulating TTN-AS1. Zhang et al. [
50] found that the lncRNA KCNQ1OT1 was expressed in the tumors and adjacent tissues of 30 patients with OS. The lncRNA KCNQ1OT1 inhibited miR-129-5p expression, which in turn promoted cell proliferation, invasion, drug resistance, and LARP1 expression. DNMT1-mediated Kcnq1 expression increases with the knock-out of KCNQ1OT1, making OS cells more sensitive to cisplatin [
51]. By focusing on the miR-130a-3p/SP1 axis, MIR17HG helps OS cells develop cisplatin resistance [
46]. Doxorubicin-resistant OS cells and tissues had lower levels of the lncRNA FENDRR, which was linked to worse prognoses in patients with OS [
52]. The lncRNA HOTAIR is upregulated in cisplatin-resistant OS tumor cells [
47]. By directly binding to and controlling miR-106a-5p, HOTAIR overexpression upregulates STAT3 expression, which is reduced in OS tissues and cisplatin-resistant cells. Cisplatin resistance and drug resistance-related gene expression in Saos2/cisplatin, MG-63/cisplatin, and U2-OS/cisplatin cells were diminished when HOTAIR was knocked down. OS tissues had considerably increased SNHG16 and ATG4B expression. A higher level of SNHG16 expression is linked to a worse prognosis in patients with OS [
48].
In OS-resistant HOS/cisplatin cells, one study found that the expression of lncRNA NORAD and MRP1 mRNA and protein was significantly elevated, while the expression levels of miR-410-3p were considerably minimized [
53]. When the lncRNA ANRIL was knocked down in U2-OS and Saos-2 OS cells, ANRIL-silenced cells became more susceptible to cisplatin [
54]. In ANRIL-silenced cells, the level of miR-125a-5p, which binds to ANRIL, increased. Furthermore, there was a decrease in the expression of STAT3, which is a target of miR-125a-5p. The researchers demonstrated that by selectively regulating miR-125a-5p, sensitivity of OS cells to cisplatin was enhanced by suppressing lncRNA ANRIL expression. Wen et al. discovered that OS cells became cisplatin-sensitive when the lncRNA-SARCC was overexpressed [
55]. Using microarray analysis, the authors found that SARCC increased miR-143 expression in OS. In contrast, SARCC and miR-143 expression were downregulated in cisplatin-resistant OS cells, making them resistant to cisplatin. In OS, miR-143 directly targets hexokinase 2 (HK2), the key enzyme in glycolysis. The RNA network SARCC-miR-143-HK may regulate OS chemosensitivity. By sponging miR-140-5p, the lncRNA MSC-AS1 triggers osteogenic differentiation [
56]. In addition, when MSC-AS1 was silenced, cisplatin became more toxic to OS cells, and overexpression of MSC-AS1 in OS patients led to a worse prognosis. Increasing miR-142 to decrease CDK6 and deactivate the PI3K/AKT axis inhibited OS cell processes in tumor cells with silenced MSC-AS1. Previous research indicated significantly increased expression of the lncRNA OIP5-AS1 in cisplatin-resistant OS cells, leading to resistance through LPAAT, PI3K, AKT, and mTOR pathways [
57]. Knocking out OIP5-AS1 effectively reduced cisplatin resistance. Knockdown of OIP5-AS1 enhanced cisplatin sensitivity in OS via the miR-377-3p and FOSL2 axes [
58], while the lncRNA ROR [
59] mediated cisplatin resistance in OS by controlling ABCB1 through miR-153-3p. NCK1-AS1 silencing restrained OS cell proliferation, migration, and invasion, and heightened their cisplatin sensitivity [
60]. Cisplatin-resistant OS cells exhibited notable upregulation of lncRNA NCK1-AS1. Overexpressing miR-137 increased OS cells' sensitivity to cisplatin, but the effects were counteracted by high levels of NCK1-AS1 in cisplatin-resistant cells. Another study discovered elevated expression of the lncRNA DNAJC3-AS1 [
61] in OS, decreasing OS sensitivity to cisplatin through a mechanistic process, which was reversed by downregulating the sense-cognate gene DNAJC3. Elevated lncRNA HOTTIP [
62] promoted chemoresistance in OS by activating the Wnt/-catenin pathway.
In summary, understanding how changes in the expression levels of lncRNAs in OS tumor cells is related to chemotherapy resistance may help in selecting and developing effective therapeutics to overcome drug resistance, thereby improving OS treatment outcomes.